Clinical trial results
for advanced
kidney cancer
For certain adults with previously untreated kidney cancer that has spread (advanced renal cell carcinoma)
Clinical trial results
for advanced
kidney cancer
For certain adults with previously untreated kidney cancer that has spread (advanced renal cell carcinoma)
Actor portrayals.
OPDIVO + CABOMETYX is not approved
for people younger than 18 years of age.
In a clinical trial of 651 people with previously untreated advanced kidney cancer that had spread, 323 people were given OPDIVO + CABOMETYX and 328 people were given SUTENT® (sunitinib malate), a standard treatment.
Half the people went without their cancer spreading, growing, or getting worse
Half the people went without their cancer spreading, growing, or getting worse
People given OPDIVO + CABOMETYX had a 49% lower risk of their cancer spreading, growing, or getting worse than those given SUTENT.
OPDIVO + CABOMETYX |
SUTENT |
Tumors disappeared completely (complete response)
Tumors shrank (partial response)
Tumors shrank or disappeared completely (overall response)
In a clinical trial, people given OPDIVO + CABOMETYX had a 40% lower risk of dying than those given SUTENT.
Words to know
Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.
Partial response is when a tumor reacts to treatment and shrinks.
Complete response is when a tumor reacts to treatment and disappears completely. This is the disappearance of any measurable tumors in response to treatment. This does not mean the cancer has been cured.
OPDIVO + CABOMETYX will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For newly diagnosed adults whose kidney cancer (renal cell carcinoma) has spread
OPDIVO® (nivolumab) is a prescription medicine used in combination with cabozantinib to treat adults with kidney cancer when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC. Please read the Patient Information that comes with cabozantinib.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.